Global Community

Americas Gold and Silver Corporation (TSXV: USA) – 5-Year Outlook (2025–2029) This analysis evaluates the potential performance of Americas Gold and Silver Corporation (TSXV: USA) over the next five years, based on the assumptions: successful production at Cosalá Operations (including the EC120 project) and the Galena Complex, a silver price of $100/oz, gold price of $4,000/oz, oil price of $60/barrel, 7.5% annual inflation, a gold and silver bull market from 2025–2029 and no stock dilution. All financial figures are in USD unless otherwise stated.

This stock was affected by the Tritium Collapse (losing sales momentum for two years), but remains a significant and efficient supplier of EV Rectifiers. It has a large European customer as well as Australian Defence and Telecommunications.

SaaS Model Maturation : As aiWARE adds scale, recurring ARR could stabilize and expand, shifting the business toward consistent profitability. Sector Tailwinds : Demand for AI tools in content redaction, legal workflows, and media measurement continues rising.

M&A is back in the rig space. Shelf Drilling being bought out has set fire to the sector.

1. Platform Model: Mobility, Delivery & Logistics Uber operates a global two-sided marketplace , connecting riders, couriers, and freight shippers with independent drivers without owning vehicles or inventory.

Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u. Starts at approximately $21,338.71 USD for a monthly supply Ingrezza@ Ingrezza (valbenazine) As of July 2025 , the average pharmacy acquisition cost for Ingrezza capsules in the U.S. is approximately: $274.54 per capsule for the 60 mg and 80 mg strengths $250.16 per capsule for the 40 mg strength Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.

Unith has experienced significant growth in its Subscribing Client base over the last year, achieving an 800% growth rate. As it approaches break-even, the realistic pricing for this AI multilingual avatar software, which offers medical consultation and numerous other applications, is highly compelling.

As of 31 July 2024, Suncorp completed the sale of its banking division to ANZ, marking a significant strategic shift to become a pure-play insurance company. Almost a year into this transformation, it's worth reviewing how the business is shaping up ahead of the next reporting season.

This analysis compares three companies: DESK, SKX, and NKE, using key financial ratios across liquidity, solvency, efficiency, profitability, and valuation. Liquidity: DESK shows strong short-term financial health, with better ratios than SKX.